Navigation Links
Accera, Inc. Completes $35 Million Series C Financing
Date:11/11/2008

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. Proceeds of this financing will be used to begin sales and marketing of the company's lead product, Axona(TM) (previously known as Ketasyn), which is scheduled to launch in the United States in the first quarter of 2009.

Inventages was joined in this round by San Diego-based POSCO BioVentures and other previous private investors. Inventages and POSCO participated in the Company's Series A and B rounds.

Steve Orndorff, Ph.D., Accera's founder and CEO, said, "Closing this transaction in the current difficult financial environment is a testament to the confidence of our investors in the Accera organization and the potential of Axona".

Wolfgang Reichenberger, Ph.D., general partner, Inventages WHealth Management Inc. and IVC Americas SA and a member of Accera's Board of Directors, expressed enthusiasm about the commercial direction of the company and the upcoming launch of Axona. "Metabolic intervention is a new approach to neurodegenerative diseases, and Accera is a clear leader. We are pleased to support the commercialization of Axona as the lead product from this novel technology platform," Reichenberger said.

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies by providing an alternative energy source for the brain. For more information, visit http://www.accerapharma.com.

Contacts

Media: Investors:

Kelly McKenna Greg Kading

MS&L Worldwide Vice President, Finance

(415) 293-2808 Accera, Inc.

Kelly.mckenna@mslworldwide.com (303) 999-3704

gkading@accerapharma.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
2. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
3. OncoMed Pharmaceuticals Completes Series B Financing
4. Avantium Completes EUR 18 Million Financing Round
5. Advanced Life Sciences Completes Debt Transaction
6. American Oriental Bioengineering Completes Two Acquisitions
7. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
8. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
9. S*BIO Completes US$26 Million Equity Financing
10. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
11. CeNeRx BioPharma Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, ... 31st and June 1st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/3/2016)... 2016 - And Other Rising ... of Those Competitor Biologics  - Biosimilar Drug ... Prospects ,  Who are the most important ... are their sales potentials? Discover, in our updated survey, ... opportunities and revenue forecasting. Visiongain,s ...
(Date:5/2/2016)... , May 2, 2016 Q ... its technology partner Mannin Research Inc. will be attending ... which takes place from May 1-5, 2016 in ... be meeting with its vendors and research partners. The ... development goals and other collaborative opportunities for the MAN-01 ...
(Date:4/29/2016)... Italy (PRWEB) , ... April 30, 2016 , ... The ... extraordinary textile design, the bioLogic team explored how bacterial properties can be applied to ... of using Natto bacteria, which move in response to humidity change. The team harvested ...
Breaking Biology Technology:
(Date:3/14/2016)... , March 14, 2016 NXTD ... growing mobile commerce market, announces the airing of a new ... starting the week of March 21 st .  The commercials ... including its popular Squawk on the Street show. --> ... on the growing mobile commerce market, announces the airing of ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
Breaking Biology News(10 mins):